This study looks at treating stage I-III hormone receptor positive, HER2 negative breast cancer with letrozole and simvastatin. Letrozole is a drug that blocks enzymes helping cancer grow, and simvastatin might improve its effect. The study compares how well these drugs work together versus letrozole alone. Patients are either given letrozole with simvastatin or just letrozole for 14 days before surgery. Researchers will check if simvastatin helps reduce cancer cell growth by measuring a marker called Ki67.

Key Points to Consider:

• The study lasts 14 days, with a 30-day follow-up.
• Participants take pills daily and attend scheduled visits.
• There might be side effects, and safety will be monitored closely.

Eligible participants need to be 18 or older, with specific breast cancer type and stage, and postmenopausal. If they have recent cancer treatments or certain health issues, they might not qualify. It's important to comply with study visits and procedures and provide written consent to join.